Eagle Pharmaceuticals Gets Final FDA Approval for Pemfexy

Eagle Pharmaceuticals Inc. gets final approval from U.S. FDA for Pemfexy, a branded alternative to Alimta.

• Conversion from tentative to final approval follows settlement with Eli Lilly & Co. on Dec. 13
  • Agreement allows to initial entry of Pemfexy into market on Feb. 1, 2022, and subsequent uncapped entry on April 1, 2022

To view the source of this information click here

To contact the reporter on this story:
Erin McClam in New York at emcclam@bloomberg.net

To contact the editor responsible for this story:
Sebastian Tong at stong41@bloomberg.net

© 2020 Bloomberg L.P. All rights reserved. Used with permission.